Seizure News and Research

Latest Seizure News and Research

NIH awards $1.7M grant to develop effective treatments for brain disorders

Ten percent of Americans experience a seizure in their lifetime, with three million diagnosed with epilepsy, a chronic neurological disorder. Anticonvulsant medications can mitigate the hyperactivity of neurons that leads to seizures, but not without severe side effects, including cognitive impairment.

23 Jul 2013

Children exposed to AEDs in womb at risk of early development issues: Study

Children whose mothers took antiepileptic drugs while pregnant are at increased risk of early development issues, according to a new study published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy.

18 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Scientists develop method to predict success of surgical procedure for temporal lobe epilepsy

Scientists at Bonn University Hospital and at the Max Planck Institute for neurological research in Cologne have developed a method with which the chances of success of a surgical procedure for temporal lobe epilepsy can be accurately predicted. The rate of accurate predictions is more than 90%. The results are now being presented in the scientific journal "NeuroImage:Clinical."

17 Jul 2013

Study demonstrates effectiveness of everolimus for TSC patients

A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce seizures in patients with tuberous sclerosis complex - a genetic disease characterized by benign tumors on multiple organ systems.

16 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Research roundup: 'Welcome-mat' effect of Medicaid expansion; Setting up shops; California's transition to Medicaid managed care

The number of people eligible for Medicaid who remain uninsured varies from state to state, according to the authors. But the federal health law is likely to increase the rate of enrollment for this group. The potential impact of this increase in Medicaid enrollment, also known as the 'welcome-mat' effect, is unclear.

2 Jul 2013

Study suggests patient's neurons may be altered in different ways, although resulting disease is same

Epilepsy, irregular heartbeats and other conditions caused by malfunctions in the body's nerve cells, also known as neurons, can be difficult to treat. The problem is that one medicine may help some patients but not others.

2 Jul 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

Duke Medicine researchers identify molecular target to prevent onset of epilepsy

Duke Medicine researchers have identified a receptor in the nervous system that may be key to preventing epilepsy following a prolonged period of seizures.

21 Jun 2013

Targeting particular signaling pathway can help prevent temporal lobe epilepsy, scientists report

Temporal lobe epilepsy, the most common form of epilepsy, is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families. Unfortunately, the condition is often not responsive to anticonvulsants. Now scientists report online June 20 in the Cell Press journal Neuron that targeting a particular signaling pathway in mice can prevent the development of temporal lobe epilepsy with just two weeks of treatment, offering hope that researchers will be able to develop effective drugs to mitigate recurrent seizures and the development of epilepsy.

21 Jun 2013

NACC recommendations address established pain therapies and preview potential future advances

Recommendations of the Neuromodulation Appropriateness Consensus Committee (NACC), announced at the 11th World Congress of the International Neuromodulation Society (INS), address established therapies and preview emerging and potential future advances.

13 Jun 2013

House panel to investigate alleged IRS seizure of medical records

The House Energy and Commerce Committee contacted the Internal Revenue Service Tuesday to request information about a 2011 search and seizure of as many as 60 million medical records from a California health care provider.

13 Jun 2013

New technology could improve communication and daily life of paralyzed person

Small electrodes placed on or inside the brain allow patients to interact with computers or control robotic limbs simply by thinking about how to execute those actions. This technology could improve communication and daily life for a person who is paralyzed or has lost the ability to speak from a stroke or neurodegenerative disease.

12 Jun 2013

Nimodipine reduces febrile seizures

Fever-induced childhood seizures, known as febrile seizures, can be terrifying for parents to witness. The full-body convulsions, which mostly affect children six months to five years old, can last from mere seconds up to more than 40 minutes. Currently, children are not treated with daily anticonvulsant medication to prevent these seizures even when they recur repeatedly because toxic side effects of existing treatments outweigh potential benefits.

12 Jun 2013

New minimally invasive surgery for epilepsy offers quicker recuperation time for patients

A new minimally invasive laser-based tool for epilepsy surgery offers a quicker recuperation time for patients than major surgery, Mayo Clinic researchers report. The research is ongoing, but preliminary results were recently presented at the American Academy of Neurology.

6 Jun 2013

Viewpoints: 'Good news' on Calif. insurance rates; Battle against dementia needs stronger efforts; Dental care for the disabled

The Affordable Care Act, a k a Obamacare, goes fully into effect at the beginning of next year, and predictions of disaster are being heard far and wide. ... No doubt there will be problems, as there are with any large new government initiative, and in this case, we have the added complication that many Republican governors and legislators are doing all they can to sabotage reform. Yet important new evidence - especially from California, the law's most important test case - suggests that the real Obamacare shock will be one of unexpected success (Paul Krugman, 5/26).

29 May 2013

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Acorda Therapeutics, Inc. will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, being held in Orlando, FL, May 29 - June 1.

28 May 2013

Astellas submits application for marketing approval of enzalutamide for prostate cancer

Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.

24 May 2013

Smartphone solutions for clinical trials

mHealth broadly refers to the use of a mobile device to send patient information to or from a medical service provider. In most medication management mobile applications that are out there now, the “information” sent is usually a unidirectional nagging reminder to the patient. The application may populate a diary or it may not.

24 May 2013

Seizure News and Research

Latest Seizure News and Research

NIH awards $1.7M grant to develop effective treatments for brain disorders

Children exposed to AEDs in womb at risk of early development issues: Study

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Scientists develop method to predict success of surgical procedure for temporal lobe epilepsy

Study demonstrates effectiveness of everolimus for TSC patients

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Research roundup: 'Welcome-mat' effect of Medicaid expansion; Setting up shops; California's transition to Medicaid managed care

Study suggests patient's neurons may be altered in different ways, although resulting disease is same

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Duke Medicine researchers identify molecular target to prevent onset of epilepsy

Targeting particular signaling pathway can help prevent temporal lobe epilepsy, scientists report

NACC recommendations address established pain therapies and preview potential future advances

House panel to investigate alleged IRS seizure of medical records

New technology could improve communication and daily life of paralyzed person

Nimodipine reduces febrile seizures

New minimally invasive surgery for epilepsy offers quicker recuperation time for patients

Viewpoints: 'Good news' on Calif. insurance rates; Battle against dementia needs stronger efforts; Dental care for the disabled

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Astellas submits application for marketing approval of enzalutamide for prostate cancer

Smartphone solutions for clinical trials

Everything you need to know about epilepsy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Seizure News and Research

Latest Seizure News and Research

Everything you need to know about epilepsy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in